BRAF oncogenic mutations correlate with progression rather than initiation of human melanoma

Jianli Dong, Robert G. Phelps, Rui Qiao, Shen Yao, Outhiriaradjou Benard, Zeev Ronai, Stuart A. Aaronson

Research output: Contribution to journalArticle

251 Citations (Scopus)

Abstract

BRAF oncogenic mutations have been identified in significant numbers of melanocytic lesions. To correlate BRAF mutation and melanoma progression, we screened BRAF mutations in 65 melanocytic lesions, including nevi, radial growth phase (RGP), vertical growth phase (VGP) melanomas, and melanoma metastases, as well as 25 melanoma cell lines. PCR and direct sequencing were used to analyze DNA samples extracted from laser capture microdissected tissues. A similar high frequency (62-72%) of BRAF oncogenic mutations was identified in melanocytic nevi, VGP, metastatic melanomas, and melanoma cell lines [H. Davies et al., Nature (Lond.), 417: 949-954, 2002; P. M. Pollock et al., Nat. Genet., 33: 19-20, 2002; and M. S. Brose et al., Cancer Res., 62: 6997-7000, 2002]. In striking contrast, we found BRAF lesions in only 10% of the earliest stage or RGP melanomas. These findings imply that BRAF mutations cannot be involved in the initiation of the great majority of melanomas but instead reflect a progression event with important prognostic implications in the transition from the great majority of RGP melanomas to VGP and/or metastatic melanoma.

Original languageEnglish (US)
Pages (from-to)3883-3885
Number of pages3
JournalCancer Research
Volume63
Issue number14
StatePublished - Jul 15 2003
Externally publishedYes

Fingerprint

Melanoma
Mutation
Growth
Viverridae
Pigmented Nevus
Cell Line
Nevus
Lasers
Neoplasm Metastasis
Polymerase Chain Reaction
DNA

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Dong, J., Phelps, R. G., Qiao, R., Yao, S., Benard, O., Ronai, Z., & Aaronson, S. A. (2003). BRAF oncogenic mutations correlate with progression rather than initiation of human melanoma. Cancer Research, 63(14), 3883-3885.

BRAF oncogenic mutations correlate with progression rather than initiation of human melanoma. / Dong, Jianli; Phelps, Robert G.; Qiao, Rui; Yao, Shen; Benard, Outhiriaradjou; Ronai, Zeev; Aaronson, Stuart A.

In: Cancer Research, Vol. 63, No. 14, 15.07.2003, p. 3883-3885.

Research output: Contribution to journalArticle

Dong, J, Phelps, RG, Qiao, R, Yao, S, Benard, O, Ronai, Z & Aaronson, SA 2003, 'BRAF oncogenic mutations correlate with progression rather than initiation of human melanoma', Cancer Research, vol. 63, no. 14, pp. 3883-3885.
Dong J, Phelps RG, Qiao R, Yao S, Benard O, Ronai Z et al. BRAF oncogenic mutations correlate with progression rather than initiation of human melanoma. Cancer Research. 2003 Jul 15;63(14):3883-3885.
Dong, Jianli ; Phelps, Robert G. ; Qiao, Rui ; Yao, Shen ; Benard, Outhiriaradjou ; Ronai, Zeev ; Aaronson, Stuart A. / BRAF oncogenic mutations correlate with progression rather than initiation of human melanoma. In: Cancer Research. 2003 ; Vol. 63, No. 14. pp. 3883-3885.
@article{e33488ad873942f895f120a6f1b9085a,
title = "BRAF oncogenic mutations correlate with progression rather than initiation of human melanoma",
abstract = "BRAF oncogenic mutations have been identified in significant numbers of melanocytic lesions. To correlate BRAF mutation and melanoma progression, we screened BRAF mutations in 65 melanocytic lesions, including nevi, radial growth phase (RGP), vertical growth phase (VGP) melanomas, and melanoma metastases, as well as 25 melanoma cell lines. PCR and direct sequencing were used to analyze DNA samples extracted from laser capture microdissected tissues. A similar high frequency (62-72{\%}) of BRAF oncogenic mutations was identified in melanocytic nevi, VGP, metastatic melanomas, and melanoma cell lines [H. Davies et al., Nature (Lond.), 417: 949-954, 2002; P. M. Pollock et al., Nat. Genet., 33: 19-20, 2002; and M. S. Brose et al., Cancer Res., 62: 6997-7000, 2002]. In striking contrast, we found BRAF lesions in only 10{\%} of the earliest stage or RGP melanomas. These findings imply that BRAF mutations cannot be involved in the initiation of the great majority of melanomas but instead reflect a progression event with important prognostic implications in the transition from the great majority of RGP melanomas to VGP and/or metastatic melanoma.",
author = "Jianli Dong and Phelps, {Robert G.} and Rui Qiao and Shen Yao and Outhiriaradjou Benard and Zeev Ronai and Aaronson, {Stuart A.}",
year = "2003",
month = "7",
day = "15",
language = "English (US)",
volume = "63",
pages = "3883--3885",
journal = "Journal of Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "14",

}

TY - JOUR

T1 - BRAF oncogenic mutations correlate with progression rather than initiation of human melanoma

AU - Dong, Jianli

AU - Phelps, Robert G.

AU - Qiao, Rui

AU - Yao, Shen

AU - Benard, Outhiriaradjou

AU - Ronai, Zeev

AU - Aaronson, Stuart A.

PY - 2003/7/15

Y1 - 2003/7/15

N2 - BRAF oncogenic mutations have been identified in significant numbers of melanocytic lesions. To correlate BRAF mutation and melanoma progression, we screened BRAF mutations in 65 melanocytic lesions, including nevi, radial growth phase (RGP), vertical growth phase (VGP) melanomas, and melanoma metastases, as well as 25 melanoma cell lines. PCR and direct sequencing were used to analyze DNA samples extracted from laser capture microdissected tissues. A similar high frequency (62-72%) of BRAF oncogenic mutations was identified in melanocytic nevi, VGP, metastatic melanomas, and melanoma cell lines [H. Davies et al., Nature (Lond.), 417: 949-954, 2002; P. M. Pollock et al., Nat. Genet., 33: 19-20, 2002; and M. S. Brose et al., Cancer Res., 62: 6997-7000, 2002]. In striking contrast, we found BRAF lesions in only 10% of the earliest stage or RGP melanomas. These findings imply that BRAF mutations cannot be involved in the initiation of the great majority of melanomas but instead reflect a progression event with important prognostic implications in the transition from the great majority of RGP melanomas to VGP and/or metastatic melanoma.

AB - BRAF oncogenic mutations have been identified in significant numbers of melanocytic lesions. To correlate BRAF mutation and melanoma progression, we screened BRAF mutations in 65 melanocytic lesions, including nevi, radial growth phase (RGP), vertical growth phase (VGP) melanomas, and melanoma metastases, as well as 25 melanoma cell lines. PCR and direct sequencing were used to analyze DNA samples extracted from laser capture microdissected tissues. A similar high frequency (62-72%) of BRAF oncogenic mutations was identified in melanocytic nevi, VGP, metastatic melanomas, and melanoma cell lines [H. Davies et al., Nature (Lond.), 417: 949-954, 2002; P. M. Pollock et al., Nat. Genet., 33: 19-20, 2002; and M. S. Brose et al., Cancer Res., 62: 6997-7000, 2002]. In striking contrast, we found BRAF lesions in only 10% of the earliest stage or RGP melanomas. These findings imply that BRAF mutations cannot be involved in the initiation of the great majority of melanomas but instead reflect a progression event with important prognostic implications in the transition from the great majority of RGP melanomas to VGP and/or metastatic melanoma.

UR - http://www.scopus.com/inward/record.url?scp=0042743826&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0042743826&partnerID=8YFLogxK

M3 - Article

VL - 63

SP - 3883

EP - 3885

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0008-5472

IS - 14

ER -